|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIF27 |
Gene summary for KIF27 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIF27 | Gene ID | 55582 |
| Gene name | kinesin family member 27 | |
| Gene Alias | KIF27 | |
| Cytomap | 9q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0003341 | UniProtAcc | Q86VH2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55582 | KIF27 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.03e-03 | 3.67e-01 | 0.1829 |
| 55582 | KIF27 | RNA-P3T-P3T-2 | Human | Lung | IAC | 1.31e-02 | 3.37e-01 | 0.1835 |
| 55582 | KIF27 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 3.47e-02 | 5.82e-01 | -0.0296 |
| 55582 | KIF27 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 3.02e-07 | 7.18e-01 | -0.0263 |
| 55582 | KIF27 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.97e-02 | 1.65e-01 | -0.0166 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0099111 | Lung | IAC | microtubule-based transport | 35/2061 | 190/18723 | 1.55e-03 | 1.64e-02 | 35 |
| GO:0060271 | Lung | IAC | cilium assembly | 55/2061 | 337/18723 | 1.84e-03 | 1.88e-02 | 55 |
| GO:0044782 | Lung | IAC | cilium organization | 58/2061 | 368/18723 | 3.15e-03 | 2.75e-02 | 58 |
| GO:00602711 | Lung | MIAC | cilium assembly | 37/967 | 337/18723 | 1.29e-05 | 9.85e-04 | 37 |
| GO:00447821 | Lung | MIAC | cilium organization | 38/967 | 368/18723 | 3.93e-05 | 2.08e-03 | 38 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04814 | Lung | MIAC | Motor proteins | 21/507 | 193/8465 | 5.64e-03 | 3.82e-02 | 2.76e-02 | 21 |
| hsa048141 | Lung | MIAC | Motor proteins | 21/507 | 193/8465 | 5.64e-03 | 3.82e-02 | 2.76e-02 | 21 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIF27 | SNV | Missense_Mutation | novel | c.2091N>T | p.Lys697Asn | p.K697N | Q86VH2 | protein_coding | tolerated(0.1) | benign(0.036) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| KIF27 | SNV | Missense_Mutation | c.2815N>T | p.Arg939Cys | p.R939C | Q86VH2 | protein_coding | deleterious(0) | possibly_damaging(0.826) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
| KIF27 | SNV | Missense_Mutation | c.2809A>T | p.Asn937Tyr | p.N937Y | Q86VH2 | protein_coding | deleterious(0.02) | benign(0.054) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | |
| KIF27 | SNV | Missense_Mutation | rs756868923 | c.2320N>A | p.Glu774Lys | p.E774K | Q86VH2 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIF27 | SNV | Missense_Mutation | novel | c.1844N>A | p.Arg615Gln | p.R615Q | Q86VH2 | protein_coding | tolerated(0.41) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIF27 | SNV | Missense_Mutation | c.2002N>G | p.Gln668Glu | p.Q668E | Q86VH2 | protein_coding | tolerated(0.17) | benign(0.01) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| KIF27 | SNV | Missense_Mutation | rs370478477 | c.3430N>T | p.Arg1144Trp | p.R1144W | Q86VH2 | protein_coding | deleterious(0) | benign(0.328) | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| KIF27 | SNV | Missense_Mutation | c.3028N>A | p.Ala1010Thr | p.A1010T | Q86VH2 | protein_coding | tolerated(0.34) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| KIF27 | SNV | Missense_Mutation | novel | c.3640A>C | p.Lys1214Gln | p.K1214Q | Q86VH2 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIF27 | SNV | Missense_Mutation | c.1565N>C | p.Val522Ala | p.V522A | Q86VH2 | protein_coding | tolerated(1) | benign(0.01) | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |